Chimerix Provides Recap of 2014 Events DURHAM, N.C., Dec.

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Chimerix Provides Recap of 2014 Events

DURHAM, N.C., Dec. 23, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX ), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today provided a year-end recap of 2014 highlights for the investigational oral broad-spectrum antiviral brincidofovir.

M. Michelle Berrey, M.D., M.P.H., President and CEO of Chimerix, said, "2014 was a pivotal year for brincidofovir and for Chimerix. In March we initiated the AdVise study in children with life-threatening adenovirus infection; in October we presented our initial clinical outcomes data from the first 48 subjects enrolled in AdVise, and showed the potential benefit of BCV on survival in this otherwise deadly viral infection. In late August the U.S. Centers for Disease Control and Prevention shared results of their independent studies showing in vitro activity of brincidofovir against Ebola virus. Through the last few months Chimerix has partnered with global health organizations and government agencies to advance the critical clinical studies which will help us understand the potential role of brincidofovir in treating Ebola Virus Disease, and in treating or preventing multiple life-threatening viral infections in at-risk patients. Chimerix is now poised to deliver on significant corporate and development milestones in 2015."

  • Brincidofovir for CMV: SUPPRESS – Data in Second Half 2015

Results from the 450-patient Phase 3 SUPPRESS trial for the prevention of cytomegalovirus (CMV) infection in hematopoietic cell transplant recipients are expected in the second half of 2015. If positive, these data would support the first regulatory submission for brincidofovir for the prevention of CMV infection following stem cell transplantation. There is currently no approved therapy for the prevention of CMV in these patients.

  • Brincidofovir for Adenovirus: AdVise – Additional Clinical Outcomes Data in 2015

Additional clinical outcomes data from the pilot portion of AdVise have been accepted for oral presentation at the 2015 BMT Tandem Meetings in February. There is currently no approved treatment for adenovirus infection, a too-often fatal infection in patients with compromised immune systems.  

  • Brincidofovir for Ebola Virus Disease – First Clinical Study to begin in Liberia

The critical clinical evaluation of brincidofovir for Ebola Virus Disease is advancing through a collaboration with the University of Oxford and ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium) with operational support from Médecins Sans Frontières and with funding provided by The Wellcome Trust. The World Health Organization and relevant European and African health authorities are also participating in this important clinical research. This initial clinical evaluation of brincidofovir will be a Phase 2 open-label study of up to 140 patients with confirmed Ebola Virus Disease; survival for patients who receive brincidofovir will be compared with survival for patients in the period leading up to this study. A second, controlled trial comparing brincidofovir to another potentially active investigational therapeutic is under development for conduct in Liberia or Sierra Leone through the collaboration with WHO and Oxford University.

Following the administration of brincidofovir to several patients with Ebola Virus Disease through Emergency Investigational New Drug Application (IND) or single-patient protocol, the U.S. Food and Drug Administration (FDA) authorized Study 205, a single-arm study to evaluate the safety and antiviral activity of brincidofovir in patients with confirmed Ebola Virus Disease. At this time, additional clinical or preclinical data and further discussion with the FDA are required before brincidofovir can be administered for Ebola Virus Disease via Study 205 or Emergency IND. In early 2015, Study 205 will be open at multiple medical centers in Europe and may be accessible to patients with confirmed Ebola Virus Disease.

About Brincidofovir (BCV, CMX001)

Chimerix's lead product candidate, brincidofovir, is an oral nucleotide analog that has shown in vitro antiviral activity against all five families of DNA viruses that affect humans, including viruses in the herpesvirus family and adenoviruses. In over 1,000 patients treated to date, brincidofovir has not been associated with kidney or bone marrow toxicity, side effects that can be treatment-limiting with available antivirals. Building on the positive Phase 2 results in the prevention of cytomegalovirus (CMV) infection, Chimerix initiated the SUPPRESS Phase 3 trial in 2013. If positive, data from SUPPRESS will support Chimerix's initial regulatory submission for brincidofovir for the prevention of CMV infection in adult hematopoietic cell transplant (HCT) recipients. In March 2013 Chimerix initiated AdVise, a Phase 3 trial in disseminated adenovirus infection, an often-fatal infection in immune-compromised children and adults. Chimerix has a longstanding collaboration with the Biomedical Advanced Research and Development Authority (BARDA) to develop brincidofovir as a medical countermeasure against smallpox. Brincidofovir has received FDA Fast Track designation for CMV, adenovirus, and smallpox.

About Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel oral antivirals in areas of high unmet medical need. Chimerix's proprietary technology has produced brincidofovir (BCV, CMX001), a clinical-stage nucleotide analog lipid-conjugate, which has demonstrated potent antiviral activity and safety in convenient, orally-administered dosing regimens. Chimerix is currently enrolling SUPPRESS, a Phase 3 study of brincidofovir for the prevention of cytomegalovirus (CMV) in adult hematopoietic cell transplant (HCT) recipients. Chimerix is enrolling the Phase 3 AdVise trial of brincidofovir for treatment of adenovirus (AdV) infection. Chimerix has a longstanding collaboration with BARDA to develop brincidofovir as a medical countermeasure for smallpox. For further information, please visit Chimerix's website: www.chimerix.com .

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, Dr. Berrey's statements in the second paragraph of the press release, and the information provided regarding (i) Chimerix's intended regulatory submissions, (ii) Chimerix's request for priority review and (iii) Chimerix's planned Expanded Access program for patients with disseminated adenovirus infection. While Chimerix believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements. Risks are described more fully in Chimerix's filings with the Securities and Exchange Commission, including without limitation its most recent Quarterly Report on Form 10-Q, its most recently filed Current Reports on Form 8-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Chimerix undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Joseph T. Schepers Executive Director, Investor Relations and Corporate Communications 919-287-4125

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 127

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
U.S. Patriot's Veteran Hiring Earns a Real National Nod

Updated Category News Views 5

A workforce award can be cheap wallpaper, but this one has some heft. U.S. Patriot, the veteran-founded and veteran-led military goods retailer owned by GALLS, landed on Military Times’ 2026 Best for Vets: Employers list, placing third in retail and first in Kentucky. The recognition covers 250 organizations, and this is U.S. Patriot’s fourth consecutive appearance....

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 271

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 13

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 71

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps

Updated Category News Views 30

Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....

Continue Reading
Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 292

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading
Skanska Adds $80M U.S. Tech Facility Contract to Orders

Updated Category News Views 107

An $80 million add-on is the sort of construction news that looks modest until you remember what it says about the customer relationship. Skanska has won an additional contract from an existing client for a U.S. tech facility, worth roughly SEK 760 million, and it will enter U.S. order bookings in the fourth quarter of 2026. No fireworks, no grand strategic...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 165

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 107

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading

Top 5 Most Recently Viewed Articles

Prinses Máxima Center Enhances Genomics with Callisto™ Innovation

Updated Category News Views 300

Prinses Máxima Center's Partnership with Volta Labs The Prinses Máxima Center for Pediatric Oncology is making headlines with its recent acquisition of the Callisto™ platform from Volta Labs. This major step forward aims to enhance efficiency in sample preparation across a variety of genomics workflows, specifically designed for both Illumina and Oxford Nanopore...

Continue Reading
Keros Therapeutics to Showcase Innovations at Key Conferences

Updated Category News Views 152

Exciting Participation of Keros Therapeutics in Major Conferences Keros Therapeutics, Inc. is making significant strides in the biopharmaceutical landscape by focusing on innovative therapies targeting disorders associated with the TGF-ß family of proteins. Recently, the company announced that its Chair and Chief Executive Officer, Jasbir S. Seehra, Ph.D., will represent...

Continue Reading
KULR Technology Unveils Major Licensing Breakthrough with Japan

Updated Category News Views 133

KULR Technology Group, Inc. (NYSE American: KULR) unveiled a major licensing agreement back in 2024 that had traders buzzing. This $2.35 million deal centered around their vibration reduction technology, known as KULR Xero Vibe (KXV). At first glance, it seemed like a solid step for the company into new markets, but let’s peel back the layers and see what's really...

Continue Reading
Mainz Biomed Achieves Significant Milestones and Results

Updated Category News Views 204

Mainz Biomed Reports Financial Results and Strategic Progress Lab network revenue up by 33% year-over-year. Operating loss down by 30% and net loss by 18%. Partnerships driving innovation and growth forward. Highlighting 2025 accomplishments and future goals. Mainz Biomed N.V. (NASDAQ: MYNZ), a pioneering molecular genetics diagnostic firm, has reported its financial...

Continue Reading
PioCreat Launches Innovative Mini Dental 3D Printer During Expo

Updated Category News Views 247

PioCreat Launches Innovative Mini Dental 3D Printer at Moscow Event PioCreat, a well-respected name in the 3D printing sector, made a significant impression at the dental industry's notable event, the 2025 Moscow Dental Expo. This gathering, renowned for showcasing advancements in digital dentistry, took place at Crocus-Expo IEC, attracting a wide array of international...

Continue Reading